MarketCap
Facebook
X
Telegram
Evelo Biosciences Balance Sheet 2022-2011 | EVLO
Brief overview of Evelo Biosciences's balance sheet strength
The review uses the five latest available annual reports between 2018 and 2022.
Assets declined from $159.9 million to $64.4 million, or -59.7%. The contraction calls for context such as disposals, restructuring or weaker operations.
Funding shifted toward liabilities: they gained +203%, compared with -59.7% for assets.
Negative shareholders' equity signals an accumulated net asset deficit and calls for particular caution.
Cash exceeds interest-bearing debt, producing net debt of -$2.1 million. The balance sheet therefore carries a net cash position.
Cash accounts for 74.4% of assets versus 58.2% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$529.2 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
Evelo Biosciences has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Evelo Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.07 M | -19.9 M | -37.1 M | -58.2 M | -80.8 M | -28.3 M | -5.86 M | - | - | - | - | - |
Long Term Debt |
43.6 M | 46.6 M | 30 M | 19.6 M | 12.3 M | 9.97 M | 9.93 M | - | - | - | - | - |
Long Term Debt Current |
2.26 M | 1.95 M | 1.67 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 40.3 M | 21 M | 13.7 M | 10.5 M | 10.8 M | - | - | - | - | - |
Total Current Liabilities |
12.4 M | 17.4 M | 19.8 M | 9.74 M | 9.24 M | 3.84 M | - | - | - | - | - | - |
Total Liabilities |
69.4 M | 79.2 M | 60.2 M | 30.7 M | 22.9 M | 14.8 M | 13 M | - | - | - | - | - |
Retained Earnings |
-529 M | -415 M | -293 M | -199 M | -113 M | -56.4 M | -28.3 M | - | - | - | - | - |
Total Assets |
64.4 M | 87.9 M | 90.6 M | 90.9 M | 160 M | 43.8 M | 18.6 M | - | - | - | - | - |
Cash and Cash Equivalents |
47.9 M | 68.4 M | 68.9 M | 77.8 M | 93.1 M | 38.2 M | 15.8 M | - | - | - | - | - |
Book Value |
-4.99 M | 8.67 M | 30.5 M | 60.2 M | 137 M | 29 M | 5.53 M | - | - | - | - | - |
Total Shareholders Equity |
-4.99 M | 8.67 M | 30.5 M | 60.2 M | 137 M | -54.7 M | -28.3 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Evelo Biosciences
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 43.6 M | 36.6 M | 40.7 M | 44.8 M | 46.6 M | 46.5 M | 46.5 M | 29.3 M | 30 M | 29.9 M | 19.8 M | 19.7 M | 19.6 M | 19.5 M | 14.9 M | 10.5 M | 12.3 M | 14.2 M | 14.8 M | 14.7 M | 9.97 M | 9.97 M | 9.97 M | 9.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
47.3 M | 66.9 M | 69.4 M | 69.4 M | 77 M | 76.3 M | 75.6 M | 79.2 M | 83.4 M | 83 M | 65.2 M | 60.2 M | 54.4 M | 44.7 M | 43.8 M | 30.7 M | 30.6 M | 26.1 M | 23.1 M | 22.9 M | 24.8 M | 23.2 M | 21.1 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-588 M | -576 M | -555 M | -529 M | -506 M | -475 M | -445 M | -415 M | -386 M | -352 M | -321 M | -293 M | -263 M | -243 M | -222 M | -199 M | -176 M | -155 M | -134 M | -113 M | -97.9 M | -82.1 M | -66.9 M | -56.4 M | -56.4 M | -56.4 M | -56.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
20.6 M | 20.8 M | 42 M | 64.4 M | 86.3 M | 112 M | 58.8 M | 87.9 M | 116 M | 145 M | 153 M | 90.6 M | 105 M | 114 M | 83.1 M | 90.9 M | 111 M | 126 M | 142 M | 160 M | 176 M | 188 M | 122 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
17.3 M | 7.62 M | 27.5 M | 47.9 M | 69.1 M | 92 M | 39.6 M | 68.4 M | 95.9 M | 123 M | 125 M | 68.9 M | 81.6 M | 90.2 M | 58.1 M | 77.8 M | 97.1 M | 109 M | 105 M | 93.1 M | 79.7 M | 179 M | 114 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 15.8 M | - | - | - | 3.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-26.7 M | -46.1 M | -27.4 M | -4.99 M | 9.33 M | 35.6 M | -16.8 M | 8.67 M | 33.1 M | 62.1 M | 87.8 M | 30.5 M | 50.4 M | 69.2 M | 39.3 M | 60.2 M | 80.5 M | 100 M | 119 M | 137 M | 151 M | 165 M | 101 M | 29 M | 29 M | 29 M | 29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-26.7 M | -46.1 M | -27.4 M | -4.99 M | 9.33 M | 35.6 M | -16.8 M | 8.67 M | 33.1 M | 62.1 M | 87.8 M | 30.5 M | 50.4 M | 69.2 M | 39.3 M | 60.2 M | 80.5 M | 100 M | 119 M | 137 M | 151 M | 165 M | -64.5 M | -54.7 M | -54.7 M | -54.7 M | -54.7 M | -28.3 M | - | - | - | -4.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Evelo Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
